Key result
Eight adolescents presented with perimyocarditis within 4 days of receiving a dose of the Pfizer-BioNTech COVID-19 vaccine.
Why the study?
Emergency Use Authorization of the Pfizer-BioNTech COVID-19 vaccine was expanded to include adolescents, prompting the description of subsequent perimyocarditis cases.
Case Report (n=8)
No
Answers are grounded in this paper and cite their sources.
The BNT162b2 COVID-19 vaccine may be associated with the development of perimyocarditis in adolescents within days of administration.
On May 10, 2021, the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) was expanded to include adolescents (May 10, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use). We describe clinical characteristics of 8 adolescents who presented over the course of 36 days to Nicklaus Children's Hospital with perimyocarditis within 4 days of receiving a dose of BNT162b2 vaccine.
No takes yet. Share an insight, caveat, or question.
Tano et al. (2021) conducted a case report in Perimyocarditis (n=8). Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) was evaluated on Clinical characteristics of perimyocarditis. Eight adolescents presented with perimyocarditis within 4 days of receiving a dose of the Pfizer-BioNTech COVID-19 vaccine.
Synapse has enriched 10 related papers. Consider them for comparative context: